End-point definition and trial design to advance tuberculosis vaccine development
Alberto L. Garcia-Basteiro, Richard G. White, Dereck Tait, Alexander C. Schmidt, Molebogeng X. Rangaka, Matthew Quaife, Elisa Nemes, Robin Mogg, Philip C. Hill, Rebecca C. Harris, Willem A. Hanekom, Mike Frick, Andrew Fiore-Gartland, Tom Evans, Alemnew F. Dagnew, Gavin Churchyard, Frank Cobelens, Marcel A. Behr, Mark Hatherill
Source: Eur Respir Rev, 31 (164) 220044; 10.1183/16000617.0044-2022
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Alberto L. Garcia-Basteiro, Richard G. White, Dereck Tait, Alexander C. Schmidt, Molebogeng X. Rangaka, Matthew Quaife, Elisa Nemes, Robin Mogg, Philip C. Hill, Rebecca C. Harris, Willem A. Hanekom, Mike Frick, Andrew Fiore-Gartland, Tom Evans, Alemnew F. Dagnew, Gavin Churchyard, Frank Cobelens, Marcel A. Behr, Mark Hatherill. End-point definition and trial design to advance tuberculosis vaccine development. Eur Respir Rev, 31 (164) 220044; 10.1183/16000617.0044-2022
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|